Rowan University Rowan Digital Works

Rowan-Virtua Research Day

25th Annual Research Day

May 6th, 12:00 AM

Persistent Neurocognitive Impairment and Neurological Complications Following COVID-19: Challenges of the Long COVID Syndrome

Timothy Wong Rowan University

Sung Kang Rowan University

Munaza Khan Rowan University

Follow this and additional works at: https://rdw.rowan.edu/stratford_research_day

Part of the Nervous System Diseases Commons, Pathological Conditions, Signs and Symptoms Commons, and the Virus Diseases Commons Let us know how access to this document benefits you - share your thoughts on our feedback

form.

Wong, Timothy; Kang, Sung; and Khan, Munaza, "Persistent Neurocognitive Impairment and Neurological Complications Following COVID-19: Challenges of the Long COVID Syndrome" (2021). *Rowan-Virtua Research Day*. 100. https://rdw.rowan.edu/stratford_research_day/2021/may6/100

This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital Works. It has been accepted for inclusion in Rowan-Virtua Research Day by an authorized administrator of Rowan Digital Works.



OSTEOPATHIC MEDICINE

SIGNIFICANCE

Coronavirus disease 2019 (COVID-19) is a highly contagious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2)¹. As of April 23rd, 2021, there are close to 150 million cumulative cases, with over 3 million deaths worldwide². In terms of clinical presentation, individuals afflicted with COVID-19 vary greatly in terms of their disease progression and symptomatology^{3,4}. During the acute phase of COVID-19, patients may experience flu-like symptoms including fever, cough, dyspnea, headache⁵⁻⁷, though gastrointestinal, renal, hepatological, rheumatological, and neurological symptoms and complications have been reported^{8,9}. Recently, there has been increasing interest in the chronic sequelae of COVID-19¹⁰. One study has estimated that over 87% of COVID patients continue to experience at least one symptom, two months after COVID symptom onset¹¹. The etiology and clinical profile of the so-called long COVID¹² is still under investigation, but some studies have suggested that long COVID may involve respiratory, neuropsychiatric, cardiovascular, immunological symptoms¹³⁻¹⁶. With the likely devastating disease burden of long COVID, clinicians need to understand the presentation and management of patients suffering from long COVID symptoms.

CASE PRESENTATION

Patient is an 86-year-old male with unspecified psychiatric history, who was admitted to the hospital with the chief complaints of urinary retention and altered mental status. Psychiatry was consulted for possible delirium. During our initial assessment, patient's presentation was suggestive of delirium. However, in our discussions with the patient's family, they revealed that the patient has had a significant decline in his mentation during the past month. Patient was hospitalized 3 weeks ago for COVID-19; he was treated with IV steroids and remdesivir, and discharged home with supplemental oxygen. While his acute symptoms of fever and dyspnea have improved, family noticed that patient has not been able to regain his premorbid functional status.

Persistent Neurocognitive Impairment and Neurological Complications Following COVID-19 – Challenges of the Long COVID Syndrome

Timothy Wong, DO, Sung Kang, DO, Munaza Khan, MD Department of Psychiatry, Rowan University School of Osteopathic Medicine, Stratford, New Jersey



Figure 1 – Patient's CT head imaging suggesting L occipital infarct



Figure 2 – Patient's MRI head imaging showing subacute L occipital lobe infarct

In particular, patient could not ambulate on his own in his wheelchairs, and more concerningly, patient could no longer converse meaningfully with family members. Psychiatry team has not been able to conduct a detailed neurocognitive assessment. During this hospitalization, patient was also found to have a subacute left occipital lobe infarct, which may have further contributed to the patient's presentation. Patient has a prolonged hospital course, complicated by multiple medical co-morbidities. The psychiatry team has managed the patient's delirium with quetiapine, risperidone, and haloperidol at different points during his hospitalization. Patient has been in the hospital for almost 1 month before he was medically stable for discharge home; however, based on input from his family, patient's mentation has yet to recover back to pre-COVID-19 level.

We reported here on a patient with persistent neurocognitive impairment and neurological complications following COVID-19. COVID-19 has been associated with a host of acute and long-term neurological symptoms and complications, including cognitive impairment, memory difficulties, psychiatric symptoms, and cerebrovascular events^{17,18}. For our patient, he experienced a notable decline in his neurocognitive functioning since COVID-19, with minimal recovery over one month after initial infection. It is also possible that the stroke he suffered may be due in part to COVID-19. COVID-19 has had a devastating impact on his functional ability and cognitive status, and his decline is further felt by his family members who are his primary caregivers. Education of patient and family members is particularly important during these uncertain times. Patients with long COVID neuropsychiatric complications will further benefit from outpatient evaluations and follow-up as well.

The long COVID syndrome will have enduring impact on millions of individuals, causing lasting symptoms and complications long after the resolution of acute COVID-19. It will be paramount for healthcare providers to understand the devastating effects of long COVID, and be able to manage patients with long COVID in the future.

1.Pollard, C. A., Morran, M. P., & Nestor-Kalinoski, A. L. (2020). The COVID-19 pandemic: a global health crisis. Physiological genomics, 52(11), 549–557 https://doi.org/10.1152/physiolgenomics.00089.2020 2.WHO coronavirus (COVID-19) Dashboard. (n.d.). Retrieved April 23, 2021, from https://covid19.who.int/ 3.Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England), 395(10229), 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-

4.Yuki, K., Fujiogi, M., & Koutsogiannaki, S. (2020). COVID-19 pathophysiology: A review. Clinical immunology (Orlando, Fla.), 215, 108427. https://doi.org/10.1016/j.clim.2020.108427 5.Tian, S., Chang, Z., Wang, Y., Wu, M., Zhang, W., Zhou, G., Zou, X., Tian, H., Xiao, T., Xing, J., Chen, J., Han, J., Ning, K., & Wu, T. (2020). Clinical Characteristics and Reasons for Differences in Duration From Symptom Onset to Release From Quarantine Among Patients With COVID-19 in Liaocheng, China. Frontiers in medicine, 7, 210. https://doi.org/10.3389/fmed.2020.00210 6.Li, J., Huang, D. Q., Zou, B., Yang, H., Hui, W. Z., Rui, F., Yee, N., Liu, C., Nerurkar, S. N., Kai, J., Teng, M., Li, X., Zeng, H., Borghi, J. A., Henry, L., Cheung, R., & Nguyen, M. H. (2021). Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. Journal of medical virology, 93(3), 1449–1458. https://doi.org/10.1002/jmv.26424

7.Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N., & Smith, L. (2020). Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. International journal of environmental research and public health, 17(8), 2690. https://doi.org/10.3390/ijerph17082690 8.Somani, S., & Agnihotri, S. P. (2020). Emerging Neurology of COVID-19. The Neurohospitalist, 10(4), 281–286. https://doi.org/10.1177/1941874420936096 9.Mao, R., Qiu, Y., He, J. S., Tan, J. Y., Li, X. H., Liang, J., Shen, J., Zhu, L. R., Chen, Y., Iacucci, M., Ng, S. C., Ghosh, S., & Chen, M. H. (2020). Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. The lancet. Gastroenterology & hepatology, 5(7), 667–678. https://doi.org/10.1016/S2468-1253(20)30126-0

10.NIH launches new initiative to STUDY "Long COVID". (2021, February 23). Retrieved March 17, 2021, from https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nihlaunches-new-initiative-study-long-covid 11.Carfì, A., Bernabei, R., Landi, F., & Gemelli Against COVID-19 Post-Acute Care Study Group (2020). Persistent Symptoms in Patients After Acute COVID-19. JAMA, 324(6), 603–605.

https://doi.org/10.1001/jama.2020.12603 12.Nabavi N. (2020). Long covid: How to define it and how to manage it. BMJ (Clinical research ed.), 370, m3489. https://doi.org/10.1136/bmj.m3489 13.Mandal, S., Barnett, J., Brill, S. E., Brown, J. S., Denneny, E. K., Hare, S. S., Heightman, M., Hillman, T. E., Jacob, J., Jarvis, H. C., Lipman, M., Naidu, S. B., Nair, A., Porter, J. C., Tomlinson, G. S., Hurst, J. R., & ARC Study Group (2020). 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax, thorax inl-2020-215818. Advance online publication. https://doi.org/10.1136/thorax inl-2020-215818 14.Goërtz, Y., Van Herck, M., Delbressine, J. M., Vaes, A. W., Meys, R., Machado, F., Houben-Wilke, S., Burtin, C., Posthuma, R., Franssen, F., van Loon, N., Hajian, B., Spies, Y., Vijlbrief, H van 't Hul, A. J., Janssen, D., & Spruit, M. A. (2020). Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?. ERJ open research, 6(4), 00542-2020. https://doi.org/10.1183/23120541.00542-2020

15.Huang, C., Huang, L., Wang, Y., Li, X., Ren, L., Gu, X., Kang, L., Guo, L., Liu, M., Zhou, X., Luo, J., Huang, Z., Tu, S., Zhao, Y., Chen, L., Xu, D., Li, Y., Li, C., Peng, L., Li, Y., ... Cao, B. (2021). 6month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet (London, England), 397(10270), 220–232. https://doi.org/10.1016/S0140-6736(20)32656-8 16.Halpin, S. J., McIvor, C., Whyatt, G., Adams, A., Harvey, O., McLean, L., Walshaw, C., Kemp, S., Corrado, J., Singh, R., Collins, T., O'Connor, R. J., & Sivan, M. (2021). Postdischarge ation needs in survivors of COVID-19 infection: A cross-sectional evaluation. Journal of medical virology, 93(2), 1013–1022. https://doi.org/10.1002/jmv.26368 17.Woo, M. S., Malsy, J., Pöttgen, J., Seddiq Zai, S., Ufer, F., Hadjilaou, A., Schmiedel, S., Addo, M. M., Gerloff, C., Heesen, C., Schulze Zur Wiesch, J., & Friese, M. A. (2020). Frequent neurocognitive deficits after recovery from mild COVID-19. Brain communications, 2(2), fcaa205. https://doi.org/10.1093/braincomms/fcaa205 18.Chen, X., Laurent, S., Onur, O. A., Kleineberg, N. N., Fink, G. R., Schweitzer, F., & Warnke, C. (2021). A systematic review of neurological symptoms and complications of COVID-19. Journal of neurology, 268(2), 392–402. https://doi.org/10.1007/s00415-020-10067-3

DISCUSSION

CONCLUSION

REFERENCES